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Abstract
Wnt signals exercise strong cell-biological and regenerative effects of considerable therapeutic value. There are, however,
no specific Wnt agonists and no method for in vivo delivery of purified Wnt proteins. Wnts contain lipid adducts that are
required for activity and we exploited this lipophilicity by packaging purified Wnt3a protein into lipid vesicles. Rather than
being encapsulated, Wnts are tethered to the liposomal surface, where they enhance and sustain Wnt signaling in vitro.
Molecules that effectively antagonize soluble Wnt3a protein but are ineffective against the Wnt3a signal presented by a cell
in a paracrine or autocrine manner are also unable to block liposomal Wnt3a activity, suggesting that liposomal packaging
mimics the biological state of active Wnts. When delivered subcutaneously, Wnt3a liposomes induce hair follicle neogenesis,
demonstrating their robust biological activity in a regenerative context.
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Introduction
Wnt signals are implicated in the self-renewal and proliferation
of stem cells from a variety of adult tissues [1–3] but despite
numerous large-scale screenings [4–7], no specific small molecule
Wnt agonists have been identified. As a consequence, the
therapeutic application of Wnt proteins - of which there are
potentially many [8–10] - has been severely hampered. We
exploited a unique and essential feature of Wnt proteins, their
covalent modification by several lipids, to package the purified
proteins in a manner that both stabilizes and enhances their in vivo
biological activity. Palmitoylation is essential for Wnt activity
[1,11]; therefore we reasoned that liposomes might serve as an
ideal delivery vehicle for such a hydrophobic molecule.
Liposomes are spherical nanovesicles consisting of an aqueous
core enclosed in one or more phospholipid layers (reviewed in
[12]). Initially, liposomes were developed in an attempt to improve
the pharmacokinetics and tissue distribution of chemotherapeutic
agents [13–15]. Consequently, bioengineers and chemical engi-
neers have invested considerable time and effort into manufac-
turing liposomes that retain the drug or molecule of interest and
prevent its degradation. Such preparations would ideally effec-
tively evade detection by the reticuloendothelial system; could be
targeted to the tissue of interest; and could be induced to release
the drug/molecule when required. For example, the addition of
polyethylene glycol (PEG) can prolong the circulatory half-life of
liposomes, perhaps acting through steric hindrance ([14–16];
reviewed in [17]).
At present, the primary application for liposome technology is
for the treatment of cancers (reviewed in [14,15,18]). In this
clinical scenario, the objective is to deliver cytotoxic drugs to a
tumor whilst simultaneously preserving cell viability in the rest of
the body. Our objective differed slightly: we wanted to develop a
method to deliver Wnts to a tissue that simultaneously preserved
biological activity and restricted diffusion of the protein.
Materials and Methods
Purification of Wnt3a liposomes
Mouse Wnt3a protein was purified as described [1], without the
heparin purification step. The product, containing approximately
equal amounts of Wnt3a and bovine serum albumin, was
concentrated further to 250 ng/ml in PBS with 1% CHAPS.
Generating Wnt3a liposomes
Many different lipid compositions were attempted. In all cases,
14 mmol of lipid were added; when multiple lipids were used, they
were added in a 90:10:4 molar ratio as indicated. 1,2-Dipalmitoyl-
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Myristoyl-2-Palmitoyl-sn-Glycero-3-Phosphocholine (MPPC)(cat#:
850445C), 1,2-Distearoyl-sn-Glycero-3-Phosphoethanolamine-N-
[PDP(Polyethylene-Glycol)2000] (DSPE-PEG2000)(cat#:880129C),
1,2-Dimyristoyl-sn-Glycero-3-Phosphocholine (DMPC)(cat#:
850345C), and 1-Palmitoyl-2-Oleoyl-sn-Glycero-3-Phosphocholine
(POPC)(cat#:850457C) were obtained fromAvanti Polar Lipids, Inc.
(Alabaster, AL).
Unless otherwise indicated, 14 mmol of DMPC in chloroform
were dried to a thin film in a 10 ml round bottom flask using
nitrogen gas and were further evaporated in a vacuum overnight.
Purified Wnt3a in 1% CHAPS in 16PBS was then diluted in 16
PBS to a total concentration of 1–1.3 mg/ml. This solution was
then added to the 10 ml flask and vortexed vigorously until the
solution was cloudy and there was no lipid visible on the bottom of
the flask. The lipid solution was then extruded 40 times through a
100–200 nm polycarbonate membrane in a thermo-barrel ex-
truder held at 30–32uC (Avanti Polar Lipids, Inc).
To separate liposome-associated Wnt3a from free Wnt3a, the
extruded solution was spun in an Optima TLX Ultracentrifuge
(Beckman Coulter, Fullerton, CA) at 28,000 rpm for a minimum
of 30 minutes at 4uC. The supernatant was removed and the lipid
pellet re-suspended in 16 DMEM (Mediatech, Inc., Herndon,
VA). The liposomes, if not used immediately, were stored at 4uC.
Cell culture and activity assays for Wnt3a liposomes
Mouse LSL cells were grown at 37uC and 5% CO2 in 16
DMEM, 10% FBS, and 1% Penicillin/Streptomycin (Mediatech,
Inc., Herndon, VA). The cells were plated in 96-well plates with an
initial density of 25,000 cells/well and allowed to recover overnight.
The cells were then treated as described and incubated for an
additional 17 hours. As the LSL cells constitutively express b-
galactosidase and express luciferase in response to Tcf/Lef binding,
activity was assessed via the Dual-LightH Combined Reporter Gene
Assay System (Applied Biosystems). Relative luciferase units were
measured and normalized against b-galactosidase activity. Error
bars indicate standard deviation. All assays were done in triplicate.
Student’s T test was employed to determine statistical significance.
Determination of effective Wnt3a concentration in Wnt
liposomes
Increasing amounts of purified Wnt3a protein were added to
LSL cells, grown in 96-well plates, in order to generate an activity
gradient. In a parallel set of experiments, LSL cells were exposed
to different volumes of Wnt3a liposomes. All experiments were
performed in triplicate. Activity of the purified protein was then
determined by luciferase activity (as described above) and
liposomal Wnt3a activity was plotted on the same graph. From
these data we interpolated the concentration of active Wnt3a in a
given volume of liposomes.
Trypsin digestion of Wnt3a liposomes
Exo-liposomal Wnt3a protein was removed by subjecting
liposomes to trypsin digestion. Briefly, 75 ml of Wnt3a liposomes
were added to 405 mlo f1 6DMEM and 20 ml1 6Trypsin solution
(Mediatech,Inc.,Herndon, VA)for a final mixture containing4.0%
trypsin. Liposomes were then incubated at 37uC for 0, 5, 10, 15, or
20 minutes. The proteolytic reaction was quenched by the addition
of 1 ml of 16 DMEM containing 10% FBS. The samples were
ultra-centrifuged at 28,000 rpm for 30 min at 4uC; the supernatant
was then removed and the lipid pellet re-suspended in 16DMEM.
The samples were then added to LSL cells in triplicate, or prepared
for standard Western blot analysis.
Isolation and characterization of Wnt antagonists
We undertook a small molecule Wnt antagonist high-through-
put screen using a mammalian cell–based reporter assay. The
reporter plasmid (Super8xTOPflash) was stably introduced into
the mouse C3H10T1/2 cell line, and the best 10T1/2 Super8-
xTOPflash clone gave ,800 fold up-regulation of luciferase
activity after 24 hour incubation with Wnt3a conditioned media.
Under these assay conditions we screened ,205,000 small
molecule compounds at a concentration of 10 mM and identified
several potential Wnt antagonists (hereafter referred to as Ant).
These antagonists were further evaluated using a luciferase
reporter driven by the SV40 large T antigen promoter (for
detecting general non-specificity) and a minimal promoter with
multimerized Gli binding sites (for detecting activity on the
Hedgehog pathway). The primary screen hit for the compound
series described in this paper was effective at inhibiting Wnt
signaling (IC50,1–2 mM) but did not function as a Hedgehog
inhibitor (IC50.20 mM) and showed no inhibitory effect on SV40
promoter driven luciferase reporter at concentrations up to
30 mM. In the derivative Ant 1.4, either a bromide or a chlorine
atom was substituted in the ortho position to enhance activity over
the unsubstituted molecule.
Evaluation of Wnt antagonist activity in autocrine and
paracrine cultures
C3H10T1/2 cells were transfected with a Super8xTOPflash
luciferase reporter plasmid (Upstate Cell Signaling Solutions). PA-
1 cells (ATCC) were transfected with a TOPflash (Upstate Cell
Signaling Solutions) luciferase reporter plasmid. Both cell lines
were maintained using standard tissue culture protocols.
PA-1 cells exhibit autocrine Wnt signaling [19]; to monitor the
ability of antagonists to block autocrine Wnt activity, cells were
plated in 96-well plates at 20,000 cells/well in growth medium;
24 hrs later, the cells were changed to fresh growth medium and
the antagonists were added in the presence of 20% Wnt3a
condition medium, or 0.1 mg/ml purified Wnt3a protein. After
24 hrs, plates were assayed for luciferase activity with the LucLite
kit (Packard).
To test the ability of the antagonists to block an exogenous Wnt
signal and autocrine Wnt signal simultaneously, PA-1 cells
transfected with Super8xTOPflash reporter were plated as
described above; 24 hrs later, the cells were changed to fresh
growth medium and the antagonists were added in the presence of
20% Wnt3a condition medium, or 0.1 mg/ml purified Wnt3a
protein. After 24 hrs, plates were assayed for luciferase activity
with the LucLite kit (Packard).
To test the ability of the antagonists to block paracrine Wnt
signaling, we co-cultured 10T1/2 Super8xTOPflash reporter cells
with L cells stably expressing Wnt 3a protein. In all assays, hFzd8
CRD, an antagonist of Wnt signaling [19], served as a positive
control for Wnt inhibition.
Wnt antagonist activity: liposomal preparation
Wnt antagonist (Ant) 1.4Cl was diluted from 20 mM in DMSO
to final concentrations of 2 mMo r2 0mMi n1 6 DMEM. LSL
cells were treated with 15 mL of Wnt3a liposomes or 15 mLo f
purified Wnt3a protein and varying concentrations of Ant 1.4Cl
ranging from 0.01 mMt o1 0 mM and allowed to incubate
overnight. The activity assay was conducted as previously
mentioned and was conducted in triplicates. Percent inhibition
values are relative to non-antagonist treated Wnt3a liposome or
free Wnt3a protein activity as appropriate.
Liposomal Packaging of Wnt3a
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All experiments were performed in accordance with Stanford
University Animal Care and Use Committee guidelines. Six three-
week old, male CD-1 mice were purchased from Charles River
Laboratories, Inc. (Wilmington, MA). Animals were housed in a
light- and temperature-controlled environment and given food and
water ad libitum.
Before subcutaneous injection of Wnt3a/PBS liposomes, the
back of the mice was shaved and cleansed with antiseptic Betadine.
Two regions, each 1 cm in diameter, were marked approximately
5 mm lateral from the midline. Mice received subcutaneous
injections of either 20 ml Wnt3a liposomes or PBS liposomes every
other day. Tissues were harvested after 14 days (7 injections) and
fixed in 4% Paraformaldehyde overnight. Samples were processed
for paraffin embedding, sectioned at 8 mm thickness and stained
with H&E for histological evaluation.
Results
Our first goal was to determine if liposomal packaging affected
the activity of Wnt3a protein. We generated Wnt3a liposomes and
compared their activity to purified soluble Wnt3a protein using the
Figure 1. Active Wnt3a protein is associated with the exo-liposomal surface. (A) Western analyses indicated that ,70% of Wnt3a protein
added during synthesis was incorporated into the liposomes; the remaining 30% remained in the supernatant. (B) Trypsin removed liposomal Wnt3a
activity as measured in an in vitro dual-reporter assay (n=3, mean+standard deviation). (C) Western analyses demonstrated that ,20% of Wnt3a
protein incorporated into the liposomal preparation still remained following trypsin digestion. This portion (,20%) was localized to the endo-
liposomal surface where it was inactive.
doi:10.1371/journal.pone.0002930.g001
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dependent expression of luciferase in response to Wnt3a treatment
(Fig. S1).
In our initial formulation of Wnt liposomes we first tested the
activity of Wnt protein associated with a liposome. The liposomal
preparation of Wnt3a was made by combining 1.0 mg/ml of
Wnt3a protein with lipids to generate a solution with an estimated
concentration of 0.5 mg/ml. Instead of being distributed equiva-
lently in the supernatant and the pellet, however, Western blot
analyses indicated that the lipid pellet contained the majority of
the Wnt3a protein (Fig. 1A). This lipid-associated Wnt3a exhibited
activity using the same luciferase assay (Fig. 1A).
Because of its lipid modifications, we speculated that Wnt3a
protein would associate with the lipid bilayer in such a way that Wnt
positioned on the exo-liposomal surface would be available for
receptor binding but Wnt positioned in the endo-liposomal surface
would not. To test this hypothesis we subjected the Wnt3a liposomes
to trypsin digestion to remove protein on the exo-liposomal surface.
Trypsin digestion completely inactivated the Wnt3a liposomes
(Fig. 1B). The ,20% of the Wnt3a protein remained associated
withtheliposomalfractionwhereitdidnotelicitanyactivity(Fig.1C).
Wetherefore conclude that the majority (80%) of Wnt3a is positioned
on the exo-liposomal surface where it exhibits biological activity,
while a small percentage remains localized to the endo-liposomal
environment where it is unavailable for signaling (Fig. 1C).
Liposomal packaging enhances Wnt3a activity
During fabrication of Wnt3a liposomes, we calculated that
,55% of the input protein is incorporated in a manner that
exhibits biological activity, while the remaining 45% is either lost
in the supernatant, or is sequestered in the endo-liposomal space.
Does the liposomal presentation of Wnt3a affect its biological
activity? We compared the activity of Wnt3a protein against
Wnt3a liposomes containing the same concentration of active
Wnt3a on the exo-liposomal surface (Fig. 2A). Based on the use of
equivalent concentrations of active Wnt3a, we calculate that the
liposomal preparation of Wnt3a exhibits a 5-fold increase in
biological activity compared to the isolated protein (Fig. 2A).
Figure 2. Liposomal packaging of Wnt3a potentiates its biological activity. (A) Equivalent concentrations of Wnt3a and liposomal Wnt3a
were tested for their ability to stimulate luciferase activity in LSL cells. DMEM and PBS exhibited baseline activity. Wnt3a protein elicited volume-
dependent activity. An equivalent concentration of liposome-packaged Wnt3a exhibited substantially greater activity. (B) Liposomal packaging
sustained Wnt3a-dependent activity. The same volume of Wnt3a and Wnt3a liposomes elicited similar levels of activity after 24 h and 48 h in vitro.A t
72 h, however, liposomal Wnt3a exhibited greater activity than Wnt3a protein.
doi:10.1371/journal.pone.0002930.g002
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We also tested whether liposomal packaging preserved the
biological activity of Wnt3a over time. TOPflash cells were plated
at different cell densities in order to insure that cells were in the
exponential growth phase throughout the experiment. Cells were
treated with various concentrations of Wnt3a protein, or Wnt3a
liposomes that were normalized for having similar activity.
Reporter activity was determined at each time point and
normalized against cell number. We found that Wnt3a and
Wnt3a liposomes exhibited similar biological activity after 24 and
48 h in culture but Wnt3a liposomes showed significantly higher
activity after 72 h in comparison to Wnt3a protein (Fig. 2B).
Therefore, Wnt3a positioned on the exo-liposomal surface is
active, and this packaging scheme potentiates and stabilizes the
activity of Wnt3a in vitro.
We examined whether DMPC could be replaced by other lipids
with varying carbon side chain lengths (i.e. DPPC has a fourteen
carbon backbone whereas DMPC has a twelve carbon backbone).
We found that lipid formulations considerably influenced the activity
of the liposomes, with DMPC being optimal (Fig. 3), despite the fact
that Western analyses indicated that a similar amount of total protein
was incorporated into each liposomal preparation (Fig. 3).
Identification of Wnt antagonists by high through-put
screening
In parallel series of experiments, we sought to identify molecules
that were effective at inhibiting Wnt signaling. In our initial
screening we used 10T1/2 cells transfected with the Super8-
xTOPflash Wnt reporter construct, and treated the cells with
soluble Wnt3a. We focused on a molecule that blocked Wnt-
induced reporter activity (Fig. 4) and also repressed Axin2 expression
in 10T1/2 cells and SAX1 and GAD1 expression in teratocarcinoma
cells induced with exogenous Wnt3a (data not shown).
In an effort to improve potency of the antagonists we
synthesized over 200 derivatives and tested these derivatives in
the 10T1/2 Super8xTOPflash reporter assay. The most potent
antagonists had IC50s less than 1 nM, indicating over 1000-fold
enhancement in potency by chemical modification (data not
shown). Epistasis analysis indicates that this class of small-molecule
inhibitors acts upstream of b-catenin at the level of Wnt ligands or
receptors (data not shown). Of these, Ant 1.4Br and one of its
derivatives, Ant 1.4Cl, were tested further for their ability to
inhibit autocrine Wnt signaling (Fig. 4A).
Antagonists discriminate between an autocrine and an
exogenous Wnt signal
The ability of Ant 1.4Br and Ant 1.4Cl to block autocrine Wnt
signaling was tested in three separate cell lines (NCCIT, NTera2,
and PA-1) all of which were transfected with a luciferase-based
Wnt reporter construct. We compared the inhibitory effects of Ant
1.4Br and Ant 1.4Cl against hFzd8CRD. In an autocrine signaling
assay, hFzd8CRD repressed luciferase activity by 50% (Fig. 4B). In
contrast, Ant 1.4Br and 1.4Cl inhibited luciferase activity by only
10% (Fig. 4B).
Ant1.4Br and 1.4Cl were also ineffective against paracrine Wnt
signaling. When cultured alone, 10T1/2 Super8xTOPflash
reporter cells showed no luciferase activity but when co-cultured
with L cells stably expressing Wnt3a protein, then luciferase
activity was increased 25-fold, which was largely inhibited by
hFzd8-CRD (Fig. 4C). Ant 1.4Br and its derivatives, however,
were largely ineffective and only repressed luciferase activity to a
maximum of 30% (Fig. 4C).
Wnt antagonists are ineffective against liposomal Wnt
Ant1.4Br and Ant 1.4Cl compounds discriminate between
purified Wnt3a, and Wnt3a secreted from cells in a paracrine/
autocrine assay. This difference was not attributable to alterations
in the protein itself either, since the paracrine Wnt signal was from
L cells and these were the same cells used to produce the purified
Wnt protein. Instead, these data imply that paracrine/autocrine
Figure 3. Wnt3a dependent activity is affected by lipid composition. Liposomes were made with various lipid compositions as indicated
(n=3; mean+standard deviation). (A) Different lipid compositions exhibited radically different activities in vitro. (B) Western blot analysis showed that
these differences in activity were not attributable to variations in total Wnt incorporation into the liposomal membrane.
doi:10.1371/journal.pone.0002930.g003
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(A) Structure of the 2-bromo 4,5-dimethoxysulfonamide analog (Ant 1.4Br) and 2-chloro 4,5-dimethoxysulfonamide analog (Ant 1.4Cl). (B) PA-1 cells
transfected with a SuperTOPflash Wnt reporter were treated with Ant 1.4Br, Ant 1.4Cl, or hFzd8CRD. Frzd8CRD (yellow line) reduced Wnt-dependent
luciferase activity. Ant 1.4Br (red) and Ant 1.4Cl (orange) were ineffective at blocking Wnt-induced activity. (C) 10T1/2 cells transfected with a TOPflash
Wnt reporter construct were co-cultured with LSL cells secreting Wnt3a. No luciferase activity was detectable in 10T1/2 cells grown alone (control,
brown line); luciferase activity was at a maximum when cells were co-cultured with LSL cells secreting Wnt3a (blue line). Fzd8CRD (yellow) inhibited
paracrine-induced Wnt reporter activity in a dose-dependent manner, to a maximum of 90%. Ant 1.4Br (red) reduced luciferase activity by less than
20%. (D) LSL cells transfected with a TOPflash Wnt reporter construct were treated with either exogenous Wnt3a or liposomal Wnt3a in the presence
of Ant 1.4Cl or hFzd8CRD. Ant 1.4Cl inhibited exogenous Wnt3a-induced reporter activity by 80% but inhibited liposomal Wnt-induced reporter
activity by only 30%. hFzd8CRD (yellow) reduced Wnt3a-induced reporter activity by 80% in Wnt3 treated cells and by 70% in liposome treated cells.
The symbols * and # reflect statistical significance (Student’s T-test, p,0.05).
doi:10.1371/journal.pone.0002930.g004
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the purified protein. One possibility is that Wnt secreted by cells
during autocrine/paracrine signaling is associated with a lipid raft
or vesicle that facilitates its transport [21] and that liposomal
packaging mimics this biological state.
We hypothesized that association of Wnt with a lipid vesicle,
either during autocrine/paracrine signaling or when packaged in a
liposome, might impede the activity of the antagonists. We directly
tested this hypothesis by treating LSL SuperTOPflash cells with
purified Wnt3a or liposomal Wnt3a in the presence of Ant 1.4Cl.
Ant1.4Cl blocked ,80% of exogenous Wnt3a-induced luciferase
activity, which was comparable to the inhibitory effect of hFzd8-
CRD (Fig. 4D). When we treated SuperTOPflash cells with
liposomal Wnt3a and Ant1.4Cl, we observed a significant
reduction in inhibitory potential of the antagonist. Again,
hFzd8-CRD was effective in blocking liposomal Wnt3a-induced
luciferase activity (Fig. 4D). Thus, Ant 1.4Br and Ant 1.4Cl were
potent antagonists of purified Wnt3a under a variety of assay
conditions but were ineffective against autocrine, paracrine, and
liposomal Wnt3a.
Liposomal packaging of Wnt3a potentiates its biological
activity in vivo
Secreted Wnt is different than purified Wnt, perhaps because
the former is associated with a lipid raft. Some data suggest that
Wnts are associated with a lipid membrane when they are shuttled
between cells [21–23]. If this hypothesis is true then we reasoned
that the in vivo efficacy of the purified protein would be enhanced
by packaging Wnts in liposomes.
We tested the efficacy of the Wnt3a liposomes in an in vivo
context, where genetic experiments have demonstrated a function
for b-catenin dependent Wnt signaling in hair follicle neogenesis
[24]. Wnt3a liposomes or PBS (control) liposomes were injected
subcutaneously into the dorsal surface of 6 week old Axin2LacZ/+
mice, in which the LacZ gene is under control of the endogenous
Wnt target Axin2 [25,26]. Twenty-four hours later, Xgal staining
was considerably stronger in the epidermal/dermal junction and
around hair follicles in animals treated with Wnt3a liposomes
compared to those treated with PBS liposomes (n=6 for each
condition; Fig. 5A,B). The cellular distribution of the staining,
however, was unchanged (Fig. 5A,B).
We assessed the tissue response to Wnt3a liposomes. Sites
treated with PBS liposomes showed no discernable change from
un-injected controls on post-injection d14 (n=6; Fig. 5C). In sharp
contrast, sites treated with Wnt3a liposomes exhibited robust hair
follicle neogenesis (n=6; Fig. 5D). The dermal thickness was
increased by 2-fold and there were significantly more hair follicles
within that layer; in addition, the region normally containing
subcutaneous fat was filled with hair follicles (Fig. 5D).
Discussion
Liposomal packaging potentiates the effects of Wnt
proteins in vivo
Because of their potential therapeutic value, multiple large scale
screens have been conducted in an attempt to identify small
molecule agonists of the Wnt pathway [4]. Although molecules
that synergize with Wnt proteins have been uncovered, none act as
agonists in the absence of Wnts. This characteristic appears to be
unique to Wnts. Unlike other pathways regulated by lipid-
modified morphogens including Hedgehogs, Wnt signaling
requires the assembly of two receptors plus a large and complex
cytoplasmic group of molecules including Axin, Dsh, and GSK-
3b. This may indeed only by accomplished by Wnt protein in the
proper configuration and not by other molecules. Furthermore,
most assays and experiments rely on conditioned media or viral
over-expression approaches to study the effects of Wnts on cell
function, which oftentimes confounds the interpretation of
experimental results because of the inherent inability to control
the amount, duration, and activity of Wnts.
With the advent of methods to purify Wnt proteins [1,2] some
of these difficulties have been circumvented but Wnt proteins are
not stable for extended periods of time (Fig. 2). We found that
liposomal packaging enhanced and sustained the biological activity
of Wnt proteins both in vitro and in vivo (Fig. 2). Furthermore,
liposomal Wnt3a exhibited the same biological specificity as
purified Wnt3a, as demonstrated by the patterns of Xgal staining
following delivery in multiple strains of Wnt reporter mice (Fig. 5
and data not shown).
Liposomal packaging mimics biological transport
Wnt proteins contain a lipid adduct that is required for activity
([1]; reviewed in [27,28]) but precisely how this lipid modification
affects the intercellular transport of Wnt proteins is unclear. Some
evidence suggests that palmitoylation is required for Wnt secretion
[29,30]. The lipid adduct may be the method by which Wnt is
Figure 5. Wnt3a liposomes have in vivo activity. (A) Equal
volumes of PBS or Wnt3a liposomes were injected subcutaneously into
Axin2LacZ/+ reporter mice. Xgal staining at 24 h revealed reporter
activity in cells at the epidermal/dermal junction and surrounding hair
follicles (arrows). (B) Treatment with Wnt3a liposomes resulted in
stronger Xgal staining with no change in the distribution of reporter
activity. Over the intervening time period, both groups received
injections of PBS liposomes or Wnt3a liposomes every other day. On
day 14, tissues were collected. (C) Repeated injection of PBS liposomes
had no effect on dermal thickness or hair follicle number (n=6). (D) In
contrast, repeated injections of Wnt3a liposomes resulted in dermal
thickening and a dramatic increase in the number of hair follicles at the
site of injection (n=6). e, epidermis; d, dermis; scf, subcutaneous fat; m,
muscle.
doi:10.1371/journal.pone.0002930.g005
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and thus allow local concentration of Wnt proteins to reach a
threshold level required for biological activity [31].
A biomimetic approach for Wnt delivery in vivo
In Drosophila there is some evidence suggesting that the Wg
protein is transported over many cell diameters in small vesicular
structures [22]. These data hint at an appealing hypothesis:
liposomal packaging mimics the method by which Wnts are
normally secreted from cells. Four lines of experimental evidence
support this conclusion. First, liposomal packaging potentiates the
activity of purified Wnt3a. Second, Wnt antagonists that are
effective against purified protein and are ineffective against Wnt
secreted from cells are also ineffective against liposomal Wnt. This
selective antagonism is likely due to interactions between the
antagonists and a region of the Wnt protein that is available in its
purified state, but hidden when Wnt is secreted in a paracrine
manner or if Wnt is associated with a liposome. Third, liposomal
Wnt3a increases reporter activity in vivo but does not alter the
distribution of Wnt responsive cells. These data suggest that
liposomal Wnt3a acts similar to endogenous Wnts. Fourth, Wnt3a
liposomes exhibit robust activity in a biologically relevant model of
hair follicle neogenesis.
Therapeutic strategies to exploit liposomal Wnts
Given the role of Wnt signaling in many regenerative processes
(planaria; fish tails) the delivery of Wnt protein as a biological
reagent has obvious clinical applications. In addition to its well
described role in inducing hair development and growth [24,32],
Wnts are also implicated in the self-renewal and proliferation of
hematopoietic stem cells [2]; mesenchymal stem cells; and neural
stem cells. Wnts may also be an effective means to stimulate bone
formation after injury or in disease states such as osteoporosis [33].
Any strategy that attempts to target the Wnt pathway to augment
tissue regeneration will have to take into consideration the need to
selectively and locally activate signaling in the tissue or area of
interest, whilst simultaneously restricting Wnt signaling in other
parts of the body. Future experiments will focus on the potential to
stimulate tissue regeneration using Wnt liposome based approaches.
Supporting Information
Figure S1 Liposomal packaging does not impair Wnt activity.
(A) An in vitro Wnt3a activity gradient was generated by
measuring activity with increasing Wnt3a concentrations in the
media. (B) Different volumes of liposomal Wnt3a and purified
Wnt3a were added to LSL cells; the activity of liposomal Wnt3a
corresponded to an effective Wnt3a concentration of 1.0 mg/ml.
(n=3; mean+standard deviation).
Found at: doi:10.1371/journal.pone.0002930.s001 (2.51 MB
DOC)
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